UNDERSTANDING CLINICAL TRIAL PHASES
RESEARCH LIBRARY • CLINICAL RESEARCH FUNDAMENTALS
From Early Human Testing to FDA Review
Clinical trials are conducted in stages designed to answer different questions about an investigational drug or biologic. Understanding these phases makes it easier to interpret research responsibly and recognize the difference between early evidence, promising results, and established clinical evidence.
A compound entering human trials has not automatically been proven safe or effective. Each phase adds a different layer of evidence.
WHY ARE CLINICAL TRIALS DIVIDED INTO PHASES?
Before a new drug can be widely used, researchers need to answer several different questions.
Is it reasonably safe to administer to humans?
How does the body respond to it?
What dose should be studied?
Does it actually produce the intended clinical effect?
What adverse effects occur?
How does it compare with placebo or existing treatment?
Do its benefits outweigh its risks?
Trying to answer all of these questions in one study would be impractical and potentially unsafe.
Clinical development therefore progresses through increasingly larger and more informative studies.
THE GENERAL PATH
Preclinical Research → Phase 1 → Phase 2 → Phase 3 → Regulatory Review → Phase 4
Not every compound completes this pathway.
Many investigational compounds are discontinued because of inadequate effectiveness, safety concerns, development decisions, or other factors.
BEFORE PHASE 1
PRECLINICAL RESEARCH
Before traditional human clinical trials begin, a compound is generally investigated through laboratory and animal research.
Preclinical studies may examine:
Mechanism of action
Cellular activity
Pharmacology
Toxicology
Pharmacokinetics
Potential organ toxicity
Possible starting doses for human research
These studies can provide important biological information.
However:
A result in a cell culture or animal model is not evidence that the same result will occur in humans.
This distinction is particularly important when evaluating experimental peptides, because many claims encountered online originate from preclinical rather than human research.
PRECLINICAL ≠ CLINICALLY PROVEN
A compound may demonstrate impressive effects in mice or laboratory models and still fail during human development.
Preclinical research should therefore be described as preclinical evidence, not human clinical evidence.
PHASE 1: INITIAL HUMAN SAFETY
Primary question: What happens when humans receive the compound?
Phase 1 generally represents the first major stage of human clinical investigation.
Studies are usually relatively small and focus heavily on:
Safety
Tolerability
Dose escalation
Pharmacokinetics
Pharmacodynamics
Potential adverse effects
Researchers may examine how the compound is absorbed, distributed, metabolized, and eliminated and how biological markers respond at different exposures.
WHO PARTICIPATES?
Depending on the compound and disease being investigated, Phase 1 trials may enroll healthy volunteers or people with the condition being studied.
WHAT PHASE 1 DOES NOT PROVE
A successful Phase 1 trial does not establish that a compound is an effective treatment.
A compound can appear reasonably tolerable in an early study and later fail because it does not work sufficiently or because uncommon safety problems emerge in larger populations.
EVIDENCE INTERPRETATION
Phase 1 = early human evidence
It is an important advancement beyond animal research, but it remains early in clinical development.
PHASE 2: DOES IT APPEAR TO WORK?
Primary question: Is there evidence of effectiveness in the target population?
Phase 2 studies generally involve more participants and begin examining whether the investigational treatment produces meaningful effects in people with the condition being studied.
Researchers commonly investigate:
Preliminary efficacy
Dose response
Dose selection
Short-term safety
Biological and clinical endpoints
Different treatment schedules
WHY PHASE 2 MATTERS
Phase 2 is often where researchers first obtain a meaningful indication of whether a compound's biological promise translates into a measurable human clinical effect.
A successful Phase 2 study can be very encouraging.
It is still not equivalent to regulatory approval or definitive proof.
AN IMPORTANT EXAMPLE
A peptide may produce substantial results in a well-designed Phase 2 trial.
That means there is legitimate human evidence supporting continued investigation.
It does not mean the compound is FDA approved, that long-term safety is established, or that the same results will occur outside the population and conditions studied.
EVIDENCE INTERPRETATION
Phase 2 = preliminary human efficacy evidence
Stronger than Phase 1, but generally still investigational.
PHASE 3: LARGE-SCALE CONFIRMATION
Primary question: Do the benefits and risks hold up in larger, more rigorous studies?
Phase 3 trials generally involve substantially larger populations and are designed to confirm findings from earlier research.
They may evaluate:
Clinical effectiveness
Safety across larger populations
Less common adverse effects
Different patient groups
Longer treatment periods
Comparison with placebo
Comparison with established treatment
Clinically meaningful outcomes
Phase 3 programs frequently include randomized, controlled, and blinded studies when appropriate.
WHY PHASE 3 IS SO IMPORTANT
A promising effect observed in a smaller Phase 2 trial needs to remain convincing when studied across a much larger and more diverse population.
Larger trials also provide substantially more safety exposure.
DOES PHASE 3 MEAN FDA APPROVED?
No.
A compound undergoing Phase 3 trials remains investigational unless it already has approval for another use.
Even positive Phase 3 results do not themselves constitute FDA approval.
The sponsor generally must submit the appropriate application to the FDA, and regulators independently review the evidence.
EVIDENCE INTERPRETATION
Phase 3 = advanced confirmatory human evidence
This can represent very strong clinical evidence, but regulatory approval remains a separate step.
REGULATORY REVIEW
WHAT HAPPENS AFTER CLINICAL TRIALS?
Successful clinical development may lead a sponsor to submit an application requesting authorization to market the product.
For drugs, this commonly involves a New Drug Application, or NDA.
For biologics, the applicable pathway may involve a Biologics License Application, or BLA.
Regulators evaluate a much broader body of evidence than a single favorable study.
Review can include:
Clinical efficacy
Safety
Benefit-risk balance
Manufacturing quality
Product consistency
Labeling
Proposed indications
Pharmacology
Supporting preclinical evidence
FDA APPROVAL IS PRODUCT SPECIFIC
This distinction is essential for interpreting peptide research.
FDA approval applies to a specific drug product for specific approved conditions of use.
Evidence involving an FDA-approved pharmaceutical product does not automatically establish that an unrelated research-grade, compounded, or differently formulated product has the same regulatory status, quality, safety, or effectiveness.
PHASE 4: AFTER APPROVAL
Primary question: What do we learn when the product is used more broadly?
Clinical research does not necessarily end after approval.
Phase 4 and other postmarketing studies can examine:
Long-term safety
Rare adverse events
Real-world effectiveness
Specific populations
Drug interactions
Longer-term outcomes
Additional clinical questions
WHY POSTMARKETING DATA MATTER
Even very large Phase 3 programs involve a limited number of people compared with eventual widespread use.
An adverse event occurring once in tens of thousands of people may therefore become apparent only after much broader exposure.
Regulatory agencies can continue evaluating safety information throughout a product's life cycle.
WHAT THE PHASES ACTUALLY TELL YOU
EVIDENCE IS A CONTINUUM
Clinical-trial phases are useful, but the phase number alone does not tell you whether a study is good or whether a claim is justified.
A responsible interpretation also considers:
Study design
Was the trial randomized?
Was there a control group?
Was it blinded?
Population
Who was actually studied?
Do they resemble the population being discussed?
Sample size
Was the trial large enough to answer its question reliably?
Endpoint
Did researchers measure a meaningful clinical outcome or only a laboratory marker?
Duration
Was the compound studied for weeks, months, or years?
Comparator
Was it compared with placebo, standard treatment, or nothing?
Statistical significance
Could the observed difference reasonably be explained by chance?
Clinical significance
Was the difference large enough to actually matter?
Publication status
Are the results published in a peer-reviewed journal, presented at a scientific meeting, or only announced in a company press release?
COMMON RESEARCH INTERPRETATION MISTAKES
“IT HAS BEEN STUDIED” DOES NOT MEAN “IT WORKS”
This is one of the most important principles in research literacy.
A compound may have:
Laboratory studies
Animal studies
A Phase 1 trial
A Phase 2 trial
An ongoing Phase 3 program
None of these descriptions should be replaced with the blanket statement “clinically proven.”
“HUMAN STUDY” DOES NOT ALWAYS MEAN STRONG EVIDENCE
A study involving humans may still be:
Very small
Uncontrolled
Observational
Short in duration
Designed primarily to evaluate safety
A case report
A retrospective analysis
The words “human study” alone tell us very little about evidence quality.
“PHASE 3” DOES NOT MEAN “FDA APPROVED”
Phase 3 describes a stage of clinical investigation.
FDA approval is a regulatory determination.
They are related, but they are not interchangeable.
“FDA APPROVED” DOES NOT MEAN “APPROVED FOR EVERYTHING”
A drug may be approved for one indication while researchers investigate it for several others.
Those uses have different regulatory and evidence contexts.
HOW CROIX DESCRIBES EVIDENCE
OUR EVIDENCE FRAMEWORK
Throughout the Croix Research Library and Compound Research Profiles, evidence should be identified according to what the research actually supports.
PRECLINICAL
Laboratory or animal research.
LIMITED HUMAN EVIDENCE
Human information exists, but the evidence remains small, preliminary, observational, or otherwise limited.
PHASE 1
Early human safety and pharmacology research.
PHASE 2
Human evidence investigating preliminary efficacy, dose, and safety.
PHASE 3
Large-scale confirmatory clinical investigation.
SUBSTANTIAL HUMAN EVIDENCE
Multiple well-designed human studies provide a meaningful clinical evidence base.
FDA APPROVED
A specific drug product has completed the applicable regulatory review and received FDA approval for defined use.
INVESTIGATIONAL
The compound or use remains under investigation and has not received FDA approval for that purpose.
AUTHORITATIVE RESOURCES
U.S. Food & Drug Administration
The Drug Development Process
Overview of discovery, preclinical research, clinical research, FDA review, and postmarket safety monitoring.
U.S. Food & Drug Administration
Step 3: Clinical Research
FDA overview of clinical research design and the phases of human drug development.
National Institutes of Health / ClinicalTrials.gov
Learn About Studies
Educational information explaining clinical studies, research participation, and clinical-trial terminology.
National Cancer Institute
Phases of Clinical Trials
Educational explanation of Phase 1 through Phase 4 clinical research.
RESEARCH NOTE
Clinical development does not always follow a perfectly rigid sequence.
Phases can overlap, trials can combine characteristics of more than one phase, and study design depends on the compound, disease, population, and regulatory pathway.
The phase should therefore be understood as one part of evaluating the strength of evidence, not as a quality score by itself.
Continue Learning: explore more articles
RESEARCH FOUNDATIONS
Human vs. Preclinical Research
Why results from cells, animals and humans answer different questions.
Understanding Clinical Trial Phases
What Phase 1, Phase 2 and Phase 3 studies are designed to investigate.
FDA Approved vs. Off Label vs. Investigational
Terms that are frequently confused in discussions of peptide research.
LABORATORY & QUALITY
How to Read a Certificate of Analysis
HPLC and Peptide Purity Explained
Identity, Sterility & Endotoxin Testing Explained
What a COA Can and Cannot Tell You
RESEARCH & EDUCATIONAL INFORMATION
This article is provided for research and educational reference and does not constitute individualized medical advice.
Clinical-trial phases describe stages of investigation designed to answer different questions about safety, dose, pharmacology, and effectiveness.
Early human research should not be interpreted as established clinical efficacy, and positive clinical-trial results should not be represented as FDA approval unless the relevant drug product has actually received that approval.
When reviewing a peptide or related compound, Croix distinguishes between laboratory evidence, animal research, human clinical evidence, investigational status, and FDA-approved drug products so that the strength of the evidence remains clear.